Cornil I, Kerbel R S, Dennis J W
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario.
J Cell Biol. 1990 Aug;111(2):773-81. doi: 10.1083/jcb.111.2.773.
Cell surface carbohydrate structures acting as ligands for tissue specific mammalian lectins have been implicated in cell-cell interactions during embryogenesis, lymphocyte homing, and tumor cell metastasis. In this report, we provide evidence that beta 1-4 linked galactose (Gal) residues in N-linked oligosaccharides on the surface of blood born tumor cells serve as a ligand for binding to microvascular endothelial cells. D36W25, a class 1 glycosylation mutant of the MDAY-D2 lymphoreticular tumor cell line, lacks sialic acid and Gal in cellular glycans due to a defect in the Golgi UDP-Gal transporter. Using UDP-Gal and bovine galactosyltransferase in vitro, beta 1-4 Gal was restored to the surface of the cells and 70% of the galactosylated glycans persisted for 8 h in vitro at 37 degrees C. Compared to mock-treated D36W25 cells, galactosylated D36W25 cells showed an 80% increase in binding to microvascular endothelial cell monolayers in vitro. The enhanced binding of galactosylated D36W25 cells to endothelial cell was inhibited by the addition of lactosamine-conjugated albumin to the assay. Consistent with these observations, swainsonine and castinospermine, two inhibitors of N-linked processing that result in loss of lactosamine antennae inhibited the binding of wild-type MDAY-D2 cells to endothelial cells in vitro. Injection of radiolabeled tumor cells into the circulation of syngeneic mice, showed that galactosylation of D36W25 cells resulted in 2-3 more tumor cells retained in the lungs and livers. In addition, galactosylation of D36W25 cells increased by 30-fold the number of visible liver metastases on inspection 4 wk after tumor cell injection. These results suggest that beta 1-4Gal-binding lectins on microvascular endothelial cells can contribute to retention and secondary tumor formation of blood born tumor cells. With the increasing availability of purified glycosyltransferases, reconstruction of a variety of carbohydrate sequences on the surface of class 1 mutants provides a controlled means of studying carbohydrate-lectin interactions on viable cells.
作为组织特异性哺乳动物凝集素配体的细胞表面碳水化合物结构,在胚胎发育、淋巴细胞归巢和肿瘤细胞转移过程中的细胞间相互作用中发挥了作用。在本报告中,我们提供证据表明,血源性肿瘤细胞表面N-连接寡糖中β1-4连接的半乳糖(Gal)残基作为与微血管内皮细胞结合的配体。D36W25是MDAY-D2淋巴网状肿瘤细胞系的1类糖基化突变体,由于高尔基体UDP-Gal转运蛋白缺陷,细胞聚糖中缺乏唾液酸和Gal。在体外使用UDP-Gal和牛半乳糖基转移酶,β1-4 Gal被恢复到细胞表面,并且70%的半乳糖基化聚糖在37℃体外持续8小时。与模拟处理的D36W25细胞相比,半乳糖基化的D36W25细胞在体外与微血管内皮细胞单层的结合增加了80%。向测定中加入乳糖胺偶联的白蛋白可抑制半乳糖基化的D36W25细胞与内皮细胞结合的增强。与这些观察结果一致,两种N-连接加工抑制剂苦马豆素和卡斯他滨,它们会导致乳糖胺天线丢失,在体外抑制了野生型MDAY-D2细胞与内皮细胞的结合。将放射性标记的肿瘤细胞注射到同基因小鼠的循环系统中,结果表明D36W25细胞的半乳糖基化导致肺部和肝脏中保留的肿瘤细胞增加2 - 3倍。此外,D36W25细胞的半乳糖基化使肿瘤细胞注射4周后检查时可见的肝转移数量增加了30倍。这些结果表明,微血管内皮细胞上的β1-4Gal结合凝集素可能有助于血源性肿瘤细胞的滞留和继发性肿瘤形成。随着纯化糖基转移酶的可得性增加,在1类突变体表面重建各种碳水化合物序列为研究活细胞上的碳水化合物-凝集素相互作用提供了一种可控手段。